These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31048944)

  • 1. Nusinersen for spinal muscular atrophy.
    Aust Prescr; 2019 Apr; 42(2):75-76. PubMed ID: 31048944
    [No Abstract]   [Full Text] [Related]  

  • 2. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
    Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
    J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
    Meylemans A; De Bleecker J
    Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lumbar laminotomy for the intrathecal administration of nusinersen for spinal muscular atrophy: technical note and outcomes.
    Ko D; Blatt D; Karam C; Gupta K; Raslan AM
    J Neurosurg Spine; 2019 Aug; 31(2):217-221. PubMed ID: 31003222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Neil EE; Bisaccia EK
    J Pediatr Pharmacol Ther; 2019; 24(3):194-203. PubMed ID: 31093018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen (Spinraza) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):50-52. PubMed ID: 28323809
    [No Abstract]   [Full Text] [Related]  

  • 17. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 18. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience].
    Walter MC; Dräger B; Günther R; Hermann A; Hagenacker T; Kleinschnitz C; Löscher W; Meyer T; Schrank B; Schwersenz I; Wurster CD; Ludolph AC; Kirschner J
    Nervenarzt; 2019 Apr; 90(4):343-351. PubMed ID: 30617569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.